Fractional dose IPV shown effective to stop outbreaks

New study shows fractional dose IPV (fIPV) boosts mucosal immunity in previously OPV-vaccinated children.

A child is vaccinated with fIPV during a campaign in Hyderabad, India. © WHO/Harish Verma
A child is vaccinated with fIPV during a campaign in Hyderabad, India. © WHO/Harish Verma

A new study published this month in the Journal of Infectious Diseases has shown that a single dose of fractional dose inactivated poliovirus vaccine (fIPV) boosts mucosal immunity to a similar degree as a full dose of IPV, in children previously immunized with oral polio vaccine (OPV). During the current IPV shortage, this vaccine is not recommended for outbreak response, however, if it is used, then this finding provides further evidence in support of fIPV rather than full dose IPV at a time of IPV global supply shortage.

The efficacy of fIPV in boosting humoral immunity (offering individual protection against paralytic disease) in comparison to full-dose IPV had already been established, and this dose-sparing approach for routine immunization programmes was subsequently recommended by the Strategic Advisory Group of Experts on immunization (SAGE). Thanks to an increasing number of countries adopting this approach, including Bangladesh, India, Nepal, Sri Lanka, Cuba and Ecuador, there have been significant improvements in the global supply of this vaccine.

These latest findings show that fIPV also has a significant role to play in outbreak response. Mucosal immunity is needed to interrupt person-to-person spread of the virus in a community, so is a critical factor in outbreak response. Used in conjunction with OPV, even a single dose of this formulation could now play a key role in such settings, by rapidly boosting mucosal immunity at a similar level to a full-dose IPV while using a fifth of the vaccine amount. This has clear benefits both on cost and supply.

“Globally, demand for IPV is high and the supply is constrained,” commented Dr Tahir Yousafzai from Aga Khan University in Karachi, Pakistan. “As polio eradication is gradually eliminating OPV, countries will eventually rely solely on IPV, further increasing demand. Fractional IPV can stretch the limited IPV supply and provide similar humoral and mucosal protection when compared to full-dose IPV in children vaccinated with OPV. In addition, it will play an important role in stopping poliovirus transmission, and hence help in the eradication of wild poliovirus and circulating vaccine-derived poliovirus.”

For the post-polio era, the Global Polio Eradication Initiative and its partners are continuing to explore new IPV approaches to ensure an affordable and sustainable supply following global polio eradication, including through the use of IPV vaccine manufactured from Sabin strains or non-infectious materials such as virus-like particles.

Additional information:


Related News

   18/02/2019
New action plan to close gaps in polio detection
   29/01/2019
Progress in the challenging last mile of eradication
   24/01/2019
Following confirmation of circulating vaccine-derived poliovirus type 2 (cVDPV2) on 8 January 2019, planning for an outbreak response is underway.
   23/01/2019
As the Global Polio Eradication Initiative (GPEI) enters its 31st year, the Chairs of the effort’s main global advisory bodies issue an extraordinary joint statement, urging all involved in the effort to excel in their roles.
   21/12/2018
Over 140 public health experts from 22 countries gather at the 6th Regional Meeting on Polio in Guatemala
   20/12/2018
In the Horn of Africa polio outbreak, immunization efforts are focusing on a group known as “special populations”.